Jump Financial LLC Grows Stock Holdings in Xeris Biopharma Holdings, Inc. $XERS

Jump Financial LLC lifted its position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 78.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 756,403 shares of the company’s stock after purchasing an additional 332,880 shares during the period. Jump Financial LLC’s holdings in Xeris Biopharma were worth $3,532,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of XERS. Cetera Investment Advisers bought a new position in Xeris Biopharma during the 1st quarter valued at approximately $245,000. Vanguard Group Inc. increased its stake in shares of Xeris Biopharma by 2.7% during the first quarter. Vanguard Group Inc. now owns 8,109,644 shares of the company’s stock valued at $44,522,000 after buying an additional 210,581 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Xeris Biopharma by 5.2% during the first quarter. Charles Schwab Investment Management Inc. now owns 423,775 shares of the company’s stock valued at $2,327,000 after acquiring an additional 20,903 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of Xeris Biopharma by 492.8% during the first quarter. Deutsche Bank AG now owns 756,407 shares of the company’s stock valued at $4,153,000 after acquiring an additional 628,807 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its stake in Xeris Biopharma by 244.1% in the first quarter. Connor Clark & Lunn Investment Management Ltd. now owns 589,471 shares of the company’s stock worth $3,236,000 after acquiring an additional 418,139 shares during the period. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $6.94 on Thursday. The company has a 50-day moving average of $8.03 and a 200 day moving average of $6.77. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -69.39 and a beta of 0.57. Xeris Biopharma Holdings, Inc. has a 1 year low of $3.14 and a 1 year high of $10.08.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.00 EPS for the quarter, missing the consensus estimate of $0.01 by ($0.01). The company had revenue of $74.38 million for the quarter, compared to analyst estimates of $74.19 million. On average, equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on XERS shares. Piper Sandler boosted their price objective on shares of Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Xeris Biopharma in a research report on Friday, November 7th. Barclays initiated coverage on shares of Xeris Biopharma in a research note on Monday. They issued an “overweight” rating and a $9.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $9.50.

Insider Activity at Xeris Biopharma

In related news, insider John Patrick Shannon, Jr. sold 23,242 shares of the company’s stock in a transaction that occurred on Thursday, November 13th. The stock was sold at an average price of $7.46, for a total value of $173,385.32. Following the sale, the insider owned 2,643,153 shares in the company, valued at $19,717,921.38. This represents a 0.87% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Beth Hecht sold 16,667 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $7.01, for a total value of $116,835.67. Following the transaction, the insider directly owned 1,320,176 shares of the company’s stock, valued at approximately $9,254,433.76. This trade represents a 1.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 56,576 shares of company stock worth $413,557 in the last 90 days. 6.47% of the stock is currently owned by company insiders.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.